128 related articles for article (PubMed ID: 17363555)
1. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells.
Weisz L; Damalas A; Liontos M; Karakaidos P; Fontemaggi G; Maor-Aloni R; Kalis M; Levrero M; Strano S; Gorgoulis VG; Rotter V; Blandino G; Oren M
Cancer Res; 2007 Mar; 67(6):2396-401. PubMed ID: 17363555
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling.
Rahnamoun H; Lu H; Duttke SH; Benner C; Glass CK; Lauberth SM
Nat Commun; 2017 Sep; 8(1):754. PubMed ID: 28963538
[TBL] [Abstract][Full Text] [Related]
3. Inhibitor of growth tumor suppressors in cancer progression.
Piche B; Li G
Cell Mol Life Sci; 2010 Jun; 67(12):1987-99. PubMed ID: 20195696
[TBL] [Abstract][Full Text] [Related]
4. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.
Fontemaggi G; Dell'Orso S; Trisciuoglio D; Shay T; Melucci E; Fazi F; Terrenato I; Mottolese M; Muti P; Domany E; Del Bufalo D; Strano S; Blandino G
Nat Struct Mol Biol; 2009 Oct; 16(10):1086-93. PubMed ID: 19783986
[TBL] [Abstract][Full Text] [Related]
5. TP53 gain-of-function mutations promote osimertinib resistance via TNF-α-NF-κB signaling in EGFR-mutated lung cancer.
Ibusuki R; Iwama E; Shimauchi A; Tsutsumi H; Yoneshima Y; Tanaka K; Okamoto I
NPJ Precis Oncol; 2024 Mar; 8(1):60. PubMed ID: 38431700
[TBL] [Abstract][Full Text] [Related]
6. Translating p53-based therapies for cancer into the clinic.
Peuget S; Zhou X; Selivanova G
Nat Rev Cancer; 2024 Mar; 24(3):192-215. PubMed ID: 38287107
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response.
Zhao M; Wang T; Gleber-Netto FO; Chen Z; McGrail DJ; Gomez JA; Ju W; Gadhikar MA; Ma W; Shen L; Wang Q; Tang X; Pathak S; Raso MG; Burks JK; Lin SY; Wang J; Multani AS; Pickering CR; Chen J; Myers JN; Zhou G
Nat Commun; 2024 Jan; 15(1):180. PubMed ID: 38167338
[TBL] [Abstract][Full Text] [Related]
8.
Shi Y; Ren X; Cao S; Chen X; Yuan B; Brasil da Costa FH; Rodriguez Rosario AE; Corona A; Michikawa C; Veeramachaneni R; Osman AA; Xie T; Wang W; Sikora AG; Myers JN; Rangel R
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37604640
[TBL] [Abstract][Full Text] [Related]
9. E2F7 drives autotaxin/Enpp2 transcription via chromosome looping: Repression by p53 in murine but not in human carcinomas.
Lin KH; Lee SC; Dacheux MA; Norman DD; Balogh A; Bavaria M; Lee H; Tigyi G
FASEB J; 2023 Jul; 37(7):e23058. PubMed ID: 37358838
[TBL] [Abstract][Full Text] [Related]
10. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer.
Miller P; Akama-Garren EH; Owen RP; Demetriou C; Carroll TM; Slee E; Al Moussawi K; Ellis M; Goldin R; O'Neill E; Lu X
Cell Death Differ; 2023 Jul; 30(7):1619-1635. PubMed ID: 37270580
[TBL] [Abstract][Full Text] [Related]
11. Revisiting macrophages in ovarian cancer microenvironment: development, function and interaction.
El-Arabey AA; Alkhalil SS; Al-Shouli ST; Awadalla ME; Alhamdi HW; Almanaa TN; Mohamed SSEM; Abdalla M
Med Oncol; 2023 Apr; 40(5):142. PubMed ID: 37039909
[TBL] [Abstract][Full Text] [Related]
12. Common activities and predictive gene signature identified for genetic hypomorphs of
Leung JC; Leu JI; Indeglia A; Kannan T; Clarke NL; Kirven NA; Dweep H; Garlick D; Barnoud T; Kossenkov AV; George DL; Murphy ME
Proc Natl Acad Sci U S A; 2023 Feb; 120(7):e2212940120. PubMed ID: 36749725
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer.
Xiao R; You L; Zhang L; Guo X; Guo E; Zhao F; Yang B; Li X; Fu Y; Lu F; Wang Z; Liu C; Peng W; Li W; Yang X; Dou Y; Liu J; Wang W; Qin T; Cui Y; Zhang X; Li F; Jin Y; Zeng Q; Wang B; Mills GB; Chen G; Sheng X; Sun C
Adv Sci (Weinh); 2022 Jul; 9(21):e2105469. PubMed ID: 35619328
[TBL] [Abstract][Full Text] [Related]
14. Estradiol-mediated inhibition of DNMT1 decreases p53 expression to induce M2-macrophage polarization in lung cancer progression.
Chen YC; Young MJ; Chang HP; Liu CY; Lee CC; Tseng YL; Wang YC; Chang WC; Hung JJ
Oncogenesis; 2022 May; 11(1):25. PubMed ID: 35589688
[TBL] [Abstract][Full Text] [Related]
15. Should mutant TP53 be targeted for cancer therapy?
Wang Z; Strasser A; Kelly GL
Cell Death Differ; 2022 May; 29(5):911-920. PubMed ID: 35332311
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-function p53
Siolas D; Vucic E; Kurz E; Hajdu C; Bar-Sagi D
Cell Rep; 2021 Aug; 36(8):109578. PubMed ID: 34433022
[TBL] [Abstract][Full Text] [Related]
17. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.
Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R
Front Oncol; 2021; 11():642603. PubMed ID: 34178628
[TBL] [Abstract][Full Text] [Related]
18. TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell.
Lei G; Liu S; Yang X; He C
Can J Gastroenterol Hepatol; 2021; 2021():8870907. PubMed ID: 33824865
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches.
Alvarado-Ortiz E; de la Cruz-López KG; Becerril-Rico J; Sarabia-Sánchez MA; Ortiz-Sánchez E; García-Carrancá A
Front Cell Dev Biol; 2020; 8():607670. PubMed ID: 33644030
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 as a Regulator and Target of Autophagy.
Shi Y; Norberg E; Vakifahmetoglu-Norberg H
Front Oncol; 2020; 10():607149. PubMed ID: 33614491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
